From this week’s Niagen Bioscience (formerly Chromadex) earnings conference call:

CEO Rob Fried:

“The pharmaceutical application of NR continues to be an important strategic initiative for the company.

As it relates to the Phase III NO-PARK study investigating the use of NR and the treatment of Parkinson’s disease, we continue to be in consistent dialogue with the researchers and still expect that the study will be completed by June.

Once the study is completed, we will not be able to see the results for a few months, but we look forward to sharing more updates as we know them.

…you can’t interpret whether the news is good or not good by the
timing of our announcement.

And the reason for that is the study will be completed, but this is a very long, very large study. So it will take several months the researchers to compile the data and analyze the data and then share the data. But after that, they will want to get the study published, and they will write up a manuscript and submit it to several journals for peer review. And they won’t want to risk getting accepted in these journals by the data being leaked.

So it will be a while.

It could be a year or more, after June before it is publicly available.

It is possible that it is sooner than that.

But we don’t intend to rush it, it’s a great study.

We have very high hopes, but of course, we have no idea.

It’s double blinded.

Neither the participants nor the researchers have any idea about who took what and what the efficacy and the results were.

So the reason we’re hopeful is because we understand the mechanisms of action of Parkinson’s and it’s — how it relates to mitochondrial malfunctions, and that’s really where we are most effective but also there were studies that were already published that were smaller Phase I studies that indicated a benefit.

So we are hopeful, but we really have no idea”

Related:

FOLLOW us on Twitter @RaisingNAD